Overview

Phase 2a Study of MVA-BN-RSV Vaccination and RSV Challenge in Healthy Adults

Status:
Active, not recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
A Phase 2a, Randomised, Double-Blinded, Placebo-Controlled Study to Assess the Safety, Immunogenicity and Efficacy of the Recombinant MVA-BN®-RSV Vaccine against Respiratory Syncytial Virus Infection in the Virus Challenge Model in Healthy Adult Participants
Phase:
Phase 2
Details
Lead Sponsor:
Bavarian Nordic